Please assess the completion status of the following clinical trial:

Trial Title: Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary CNS non-Hodgkin's lymphoma by brain biopsy, positive cerebrospinal fluid cytology, or vitrectomy~  * Recurrent disease~* Measurable disease, define as bi-dimensionally measurable lesions with clearly defined margins by brain MRI or CT scan~  * Radiographical evidence of tumor progression by MRI or CT scan~ * Steroid therapy must be stable for 5 days prior to scan~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 60-100%~Life expectancy~* More than 8 weeks~Hematopoietic~* WBC ≥ 3,000/mm\^3~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10 g/dL (transfusion allowed)~Hepatic~* SGOT \< 2 times upper limit of normal (ULN)~* Bilirubin \< 2 times ULN~* No active or latent hepatitis B infection~Renal~* Creatinine \< 1.5 mg/dL OR~* Creatinine clearance ≥ 60 mL/min~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix~* No uncontrolled significant medical illness that would preclude study treatment~* No active infection~* No active HIV infection~* No concurrent disease that would dangerously alter drug metabolism or obscure toxicity~PRIOR CONCURRENT THERAPY:~Biologic therapy~* At least 7 days since prior interferon or thalidomide~* No concurrent prophylactic filgrastim (G-CSF)~* No concurrent immunotherapy~Chemotherapy~* No prior temozolomide~* At least 14 days since prior methotrexate~* At least 21 days since prior procarbazine~* At least 42 days since prior nitrosoureas~* No other concurrent chemotherapy~Endocrine therapy~* See Disease Characteristics~* At least 7 days since prior tamoxifen~* No concurrent hormonal therapy~Radiotherapy~* No concurrent radiotherapy~Surgery~* Not specified~Other~* Recovered from all prior therapy~* At least 28 days since prior investigational agents~* At least 28 days since other prior cytotoxic therapy~* At least 7 days since other prior non-cytotoxic agents (e.g., tretinoin) (radiosenitizers allowed)~* No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- IV Rituximab (Type: EXPERIMENTAL): IV Rituximab 750mg/m2 single infusion every week for up to 4 weeks.~Induction: Rituximab (750mg/m2) Day 1, 8, 15 and 22 and Temozolomide \[TMZ\] (150mg/m2) days 1-7 and 15-21, followed by six cycles of consolidation TMZ 150-200mg/m2 x5/28days, followed by maintenance with methylprednisolone (1g IV every 28days) until progression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues